Clinical trials: Bone Density
Product Persistence in GI Tract, Kinetics
Food Trial to Evaluate the Kinetics of the Medical Foods SBD111 and SBD121 Persistence in Healthy Adults
This study is a randomized, open-label, trial in healthy volunteers. Trial participants will be given a medical food product (combination of probiotics and prebiotics) called SBD111 or SBD121 for seven days and microbial…
- Conditions
- Product Persistence in GI Tract, Kinetics, Rheumatoid Arthritis (RA), Bone Density
- Trial name
- NCT06614166
- Testing
- SBD111 Probiotic Medical Food, SBD121 Probiotic Medical Food
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Solarea Bio, Inc
Cancer, Hematologic Malignancies
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
- Conditions
- Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology
- Trial name
- NCT01345019
- Testing
- Denosumab, Zoledronic acid, Denosumab (for the open-label treatment phase)
- Where
- 309 sites in United States, Australia and 27 more
- Volunteers
- 1,718 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
This was a prospective, randomized, open-label, two arm phase III trial designed to evaluate the efficacy and safety of zoledronic acid in preventing bone loss in postmenopausal women with operable breast cancer who had received…
- Trial name
- NCT00332709
- Testing
- Letrozole, Zoledronic acid
- Where
- 23 sites in Germany
- Volunteers
- 83 people
- Sponsor
- Novartis
Dwarfism, Pituitary, Turner Syndrome
Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)
This study is a multicenter, open-label, postmarketing surveillance study. The substudy will collect information on BMD in adolescents and young adults with GHD or Turner syndrome who are completing GH treatment for statural…
- Trial name
- NCT00097526
- Volunteers
- 125 people
- Sponsor
- Genentech, Inc.
Postmenopausal Osteoporosis, Low Bone Mass
Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass
This is a randomized, double-blind, placebo- and active-controlled Phase II study evaluating the efficacy and safety of TST002 injection (a humanized monoclonal antibody) in postmenopausal women with osteoporosis or low bone…
- Trial name
- NCT07806331
- Testing
- Denosumab
- Volunteers
- 110 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Osteoporosis, Postmenopausal
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
The purpose of this trial is to study: Effects of arzoxifene on bone fractures and bone mass. Effects of arzoxifene on getting breast cancer.
- Trial name
- NCT00088010
- Testing
- Arzoxifene
- Where
- United States
- Volunteers
- 9,369 people
- Sponsor
- Eli Lilly and Company
Osteopenia
A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass
The purpose of this study is to evaluate the effect of romosozumab on parameters of bone quality of the forearm using peripheral quantitative computed tomography (pQCT) following multiple subcutaneous dose administrations of…
- Trial name
- NCT00950950
- Testing
- Romosozumab
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amgen
Endometriosis
Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis
This study is designed to evaluate the safety and beneficial effects of elagolix (NBI-56418) compared to placebo and leuprorelin (an approved endometriosis therapy) over a three month period followed by an additional three months…
- Trial name
- NCT00797225
- Testing
- Leuprorelin Acetate Depot, Elagolix
- Volunteers
- 174 people
- Sponsor
- AbbVie
Osteoporosis
Transition From Alendronate to Romosozumab (AMG 785)
The purpose of this study is to estimate the percent change from baseline in lumbar spine bone mineral density (BMD) following multiple-dose administrations of romosozumab in postmenopausal women with low BMD previously treated…
- Trial name
- NCT01588509
- Testing
- Romosozumab
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Amgen
Breast Cancer
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
This study examines the safety and efficacy of zoledronic acid 4 mg., given every 3 months over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18 and 21) in improving bone mineral density in premenopausal women with hormone…
- Trial name
- NCT00375505
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Werner Syndrome
Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome
This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.
- Trial name
- NCT05847179
- Testing
- Progerinin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- PRG Science & Technology Co., Ltd.
Osteoporosis, Hip Fracture
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new)…
- Trial name
- NCT00046254
- Testing
- Zoledronic Acid
- Where
- 28 sites in United States, Germany
- Volunteers
- 2,127 people
- Sponsor
- Novartis Pharmaceuticals
Infection, Human Immunodeficiency Virus
Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC
Phase IV, Single-Arm, Open-Label Study Evaluating Bone Mineral Density in HIV-1-Infected Adults ≥50 Years Old Switching from EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild) to ABC/DTG/3TC (Triumeq)
- Trial name
- STRUCTR (NCT03275701)
- Testing
- Triumeq
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mills Clinical Research
Osteoporosis
CR9112792, a Follow-up of Study CR9108963
The purpose of this study is to determine whether bone mineral density has increased in a subgroup of postmenopausal osteoporotic women from study CR9108963, between 6 and 12 months following cessation of ronacaleret therapy.
- Trial name
- NCT00891553
- Testing
- DXA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 171 people
- Sponsor
- GlaxoSmithKline
Osteoporosis
A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
This study will evaluate whether teriparatide is superior to the active comparator in the change from baseline of lumbar spine BMD (bone mineral density) in men and postmenopausal women with low bone mass and a recent…
- Trial name
- MOVE (NCT00887354)
- Testing
- Teriparatide, Risedronate, Calcium
- Where
- 28 sites in United States, Canada and 10 more
- Volunteers
- 224 people
- Sponsor
- Eli Lilly and Company
Calcium, Osteopenia
Effects of Amorphous Calcium Carbonate Supplementation on Bone Health in Postmenopausal Women With Osteopenia
This research was designed in accordance to the Method for Efficacy Assessment of Health Food for Bone Heath. Changes to bone density were measured to evaluate the effectiveness of amorphous calcium carbonate in maintaining bone…
- Conditions
- Calcium, Osteopenia, Bone Mineral Density, Bone Turnover Marker
- Trial name
- NCT05810909
- Where
- Taiwan
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universal Integrated Corp.